Wells Fargo & Company Kaleido Biosciences, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.05 - $1.7 $259 - $8,811	-5,183 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.3 - $2.7 $10,190 - $21,165	-7,839 Reduced 60.2%	5,183 $8,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $6.02 $28,885 - $72,757	12,086 Added 1291.24%	13,022 $31,000
Q3 2021 Nov 15, 2021	BUY	$5.36 - $7.99 $1,742 - $2,596	325 Added 53.19%	936 $6,000
Q2 2021 Aug 16, 2021	SELL	$5.82 - $8.72 $3,014 - $4,516	-518 Reduced 45.88%	611 $5,000
Q1 2021 May 13, 2021	SELL	$7.2 - $16.82 $87,580 - $204,598	-12,164 Reduced 91.51%	1,129 $9,000
Q4 2020 Feb 09, 2021	BUY	$5.77 - $11.33 $40 - $79	7 Added 0.05%	13,293 $121,000
Q3 2020 Nov 05, 2020	SELL	$5.09 - $11.07 $11,253 - $24,475	-2,211 Reduced 14.27%	13,286 $147,000
Q2 2020 Aug 13, 2020	BUY	$4.62 - $8.01 $22,203 - $38,496	4,806 Added 44.95%	15,497 $115,000
Q1 2020 May 14, 2020	BUY	$3.62 - $9.49 $38,701 - $101,457	10,691 New	10,691 $66,000

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.